Pfizer Strategic Shift: Unveiling a New Oncology Frontier with Seagen Deal Closure
Pfizer Strategic Shift: Pfizer (PFE.N) is gearing up for the finalization of its anticipated $43 billion acquisition of cancer drugmaker Seagen (SGEN.O), projecting the deal’s closure later this week. In […]